2256.HK

Biopharmaceutical company Abbisko Cayman Ltd. (2256.HK) said on Monday that its revenue increased significantly last year, up from 19 million yuan ($2.59 million) in 2023 to 485 million yuan in 2024. As a result, the company earned a profit of 10 million yuan last year, reversing a loss of 432 million yuan the previous year.

The company said the big revenue increase and resulting profit were mostly due to its signing of an out-licensing agreement for its drug pimicotinib (ABSK021), including an upfront payment of $70 million, with Merck (MRK.US).

Shares of Abbisko opened up nearly 1% at HK$4.55 on Monday and continued to rise through the day, up 3.1% in the afternoon session. The company’s shares have more than doubled over the past year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click  here

Recent Articles

East Buy does e-commerce

Work in progress: East Buy reinvents itself – again

The former educator-turned-livestreaming e-commerce company is trying to become an online version of discount specialist Sam’s Club with its own private label business Key Takeaways: East Buy returned to profitability…